Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17450405 | 0.95 | CNR2 (0.49) | CNR2CNR1 | |
| SCHEMBL17444528 | 0.92 | CNR2 (0.67) | CNR2CNR1 | |
| SCHEMBL17444687 | 0.92 | CNR2 (0.57) | CNR2CNR1 | |
| SCHEMBL17444588 | 0.92 | CNR2 (0.60) | CNR2CNR1 | |
| SCHEMBL17444678 | 0.89 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL17444716 | 0.88 | CNR2 (0.63) | CNR2CNR1 | |
| SCHEMBL17444690 | 0.87 | CNR2 (0.59) | CNR2CNR1 | |
| SCHEMBL17444706 | 0.87 | CNR2 (0.50) | CNR2CNR1 | |
| SCHEMBL17444710 | 0.86 | CNR2 (0.53) | CNR2CNR1 | |
| SCHEMBL17444627 | 0.85 | SMPD1 (0.56) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2017-06-08 | — | — | US | disclosed |
| WO-2016008010-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
| WO-2016008010-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158636-A1 | FUNCTIONALISED AND SUBSTITUTED CARBAZOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | CNR2 2545/4885CNR1 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.